Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBLINGUALStandard

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

Standard Dose
EQ 2MG BASE;EQ 0.5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is listed in Drugs@FDA under application 219727 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE Form and strength TABLET;SUBLINGUAL - EQ 2MG BASE;EQ 0.5MG BASE Sponsor ASCENT PHARMS INC Submission history Latest submission status date: 2025-12-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is listed in Drugs@FDA under application 219727 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE Form and strength TABLET;SUBLINGUAL - EQ 2MG BASE;EQ 0.5MG BASE Sponsor ASCENT PHARMS INC Submission history Latest submission status date: 2025-12-15 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.